These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25093791)

  • 1. Psychotic episode in a patient with Alzheimer's dementia while shifting from the oral to patch form of rivastigmine.
    Ku SC; Hsu CC; Chang HA; Kao YC; Tzeng NS
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E51-2. PubMed ID: 25093791
    [No Abstract]   [Full Text] [Related]  

  • 2. A rivastigmine patch for dementia.
    Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
    Sadowsky CH; Farlow MR; Meng X; Olin JT
    Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
    Cummings J; Winblad B
    Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for dementia associated with Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
    [No Abstract]   [Full Text] [Related]  

  • 11. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
    Burian R
    MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
    Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
    Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.
    Boada M; Arranz FJ
    Dement Geriatr Cogn Disord; 2013; 35(1-2):23-33. PubMed ID: 23306147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.